Kaoru Takasaki, MD
Skip to content
MD - Yale School of Medicine, New Haven, CT
Pediatrics - Stanford, Palo Alto, CA
Pediatric Hematology/Oncology - Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatrics – American Board of Pediatrics
Instructor of Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Takasaki K, Hehir D, Raffini L, Samelson-Jones BJ, Shih E, Dain AS. Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage. Pediatr Blood Cancer. 2022 Jun;69(6):e29484. Epub 2021 Nov 22.
Takasaki K, Diaz-Stransky A, Miller G. Psychogenic Nonepileptic Seizures: Diagnosis, Management, and Bioethics. Pediatric Neurology. 2016 Apr;pii: S0887-8994(15)30402-1.
Greenfeld H*, Takasaki K*, Walsh MJ*, Ersing I, Bernhardt K, Ma Y, Fu B, Ashbaugh CW, Cabo J, Mollo SB, Zhou H, Li S, Gewurz BE. TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation. PLoS Pathogens. 2015 May;11(5): e1004890.
Zhao B, Barrera LA, Ersing I, Willox B, Schmidt SC, Greenfeld H, Zhou H, Mollo SB, Shi TT, Takasaki K, Jiang S, Cahir-McFarland E, Kellis M, Bulyk ML, Kieff E, Gewurz BE. The NF-κB genomic landscape in lymphoblastoid B cells. Cell Reports. 2014 Sep;8(5): 1595-1606.
Zhou X, Gewurz BE, Ritchie JM, Takasaki K, Greenfeld H, Kieff E, Davis BM, Waldor MK. A Vibrio parahaemolyticus T3SS effector mediates pathogenesis by independently enabling intestinal colonization and inhibiting TAK1 activation. Cell Reports. 2013 May;3(5):1690-1702.
Gewurz BE, Towfic F, Mar JC, Shinners NP, Takasaki K, Zhao B, Cahir-McFarland ED, Quackenbush J, Xavier RJ, Kieff E. Genome-wide siRNA screen for mediators of NF-κB activation. PNAS. 2012 Feb;109(7): 2467-2472.
Gewurz BE, Mar JC, Padi M, Zhao B, Shinners NP, Takasaki K, Bedoya E, Zou JY, Cahir-McFarland E, Quackenbush J, Kieff E. Canonical NF-kappaB activation is essential for Epstein-Barr virus latent membrane protein 1 TES2/CTAR2 gene regulation. Journal of Virology. 2011 July;85(13): 6764-6773.
Takasaki K, Chou ST. Rh Incompatibility. Ferri’s Clinical Advisor 2023. Providence, RI: Elsevier, 2022 (In press).
Takasaki K, Chou ST. Red cell genotyping: Real world use. Transfus Med. 2022 Jun;32(3):185-186.
Takasaki K, Chou S. Rh Incompatibility. Ferri’s Clinical Advisor 2022. Providence, RI: Elsevier, 2021.
Takasaki K, Wilkes M, Chen J, Siva K, Varetti G, Dever D, Youn M, Chae HD, Mercado J, Saxena M, Narla A, Glader B, Porteus M, Repellin C, Gaza H, Serrano M, Flygare J, Sakamaoto K. Inhibition of Nemo-like Kinase Improves Erythropoiesis in Models of Diamond Blackfan Anemia. Oral presentation at American Society of Pediatric Hematology/Oncology (ASPHO), New Orleans, May 2019.
Wilkes M, Takasaki K, Chae HD, et al. Nemo-like Kinase is hyperactive in RPS19-insufficient erythroid progenitors. Diamond Blackfan Anemia Foundation International Consensus Conference, Atlanta, March 2018.
2021-present, Ken Mizuno Fund in Hematology
2020-present, NIH/NHLBI T32 Pediatric Hematology Research Training Program
2018-2019, Stanford Pediatrics Resident Research Grant
2013-2016, Japanese Medical Society of America, Nishioka Foundation Scholarship
2013, Alex’s Lemonade Stand Foundation (ALSF), Pediatric Oncology Student Training (POST) Grant
2010, magna cum laude, Harvard College
2021-present, American Association for Cancer Research
2021-present, American Society of Clinical Oncology
2021-present, American Society of Pediatric Hematology/Oncology
2019-present, American Board of Pediatrics
2019-present, Children’s Oncology Group
2018-present, American Society of Hematology
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.